oxonic acid has been researched along with Diarrhea in 37 studies
Oxonic Acid: Antagonist of urate oxidase.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this single-arm phase II clinical trial was to evaluate whether the alternate-day administration of S-1 plus irinotecan would reduce the incidence of severe diarrhea in comparison to consecutive-day S-1 administration (standard IRIS regimen) in second-line treatment for patients with metastatic colorectal cancer." | 9.27 | A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study. ( Honda, M; Kim, HM; Kondo, K; Kosugi, C; Matsuda, C; Mishima, H; Oba, K; Sakamoto, J; Takahashi, T; Takemoto, H; Tanaka, C; Tokunaga, Y, 2018) |
| "Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC)." | 9.24 | A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. ( Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M, 2017) |
| "In Japan, a study comparing the effectiveness and safety of irinotecan plus S-1 (IRIS) with those of a combination of 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line treatment in patients with advanced or recurrent colorectal cancer demonstrated that IRIS was non-inferior to FOLFIRI." | 9.16 | Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. ( Fukushima, H; Hatanaka, K; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Munakata, M; Nakamura, M; Nakatsumi, H; Sakata, Y; Sogabe, S; Tateyama, M; Yuki, S, 2012) |
| "A combination of irinotecan with continuous intravenous infusions of 5-fluorouracil (5-FU) and leucovorin (LV) is often used to treat advanced colorectal cancer." | 9.12 | Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. ( Goto, A; Hamaguchi, T; Kato, K; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yasui, H, 2006) |
| "Gemcitabine has been standard of care in advanced pancreatic adenocarcinomas (PC) for almost two decades." | 7.88 | S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. ( Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB, 2018) |
| "The aim of this single-arm phase II clinical trial was to evaluate whether the alternate-day administration of S-1 plus irinotecan would reduce the incidence of severe diarrhea in comparison to consecutive-day S-1 administration (standard IRIS regimen) in second-line treatment for patients with metastatic colorectal cancer." | 5.27 | A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study. ( Honda, M; Kim, HM; Kondo, K; Kosugi, C; Matsuda, C; Mishima, H; Oba, K; Sakamoto, J; Takahashi, T; Takemoto, H; Tanaka, C; Tokunaga, Y, 2018) |
| "Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC)." | 5.24 | A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. ( Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M, 2017) |
| "The incidence of diarrhea during chemotherapy was significantly lower in the S-1 plus lafutidine group than in the group treated with S-1 alone (10% vs." | 5.19 | Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer. ( Hanazaki, K; Kitagawa, H; Kobayashi, M; Maeda, H; Munekage, E; Namikawa, T, 2014) |
| "In Japan, a study comparing the effectiveness and safety of irinotecan plus S-1 (IRIS) with those of a combination of 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line treatment in patients with advanced or recurrent colorectal cancer demonstrated that IRIS was non-inferior to FOLFIRI." | 5.16 | Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. ( Fukushima, H; Hatanaka, K; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Munakata, M; Nakamura, M; Nakatsumi, H; Sakata, Y; Sogabe, S; Tateyama, M; Yuki, S, 2012) |
| "A combination of irinotecan with continuous intravenous infusions of 5-fluorouracil (5-FU) and leucovorin (LV) is often used to treat advanced colorectal cancer." | 5.12 | Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. ( Goto, A; Hamaguchi, T; Kato, K; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yasui, H, 2006) |
| "Gemcitabine has been standard of care in advanced pancreatic adenocarcinomas (PC) for almost two decades." | 3.88 | S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. ( Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB, 2018) |
| "The incidence of oral mucositis was significantly lower in the treatment group (9." | 2.90 | A prospective pilot study of an elemental nutritional supplement for prevention of oral mucositis during S-1 adjuvant chemotherapy for gastric cancer. ( Kimura, A; Kogure, N; Kuwano, H; Mochiki, E; Ogata, K; Suzuki, M; Toyomasu, Y; Yanai, M; Yanoma, T, 2019) |
| "Unresectable advanced hepatocellular carcinoma is a heterogeneous disease, for which sorafenib is the first targeted agent approved for first-line therapy, and treatment options for patients with sorafenib-refractory advanced hepatocellular carcinoma are limited." | 2.84 | S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. ( Date, Y; Fang, X; Furuse, J; Hidaka, H; Ikeda, M; Kaneko, S; Kawazoe, S; Kudo, M; Moriguchi, M; Numata, K; Ohkawa, S; Okusaka, T; Sato, Y; Takeuchi, M; Tanaka, H, 2017) |
| "Irinotecan was administered on days 1, 8, 22, and 29." | 2.82 | A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1). ( Baba, H; Hayakawa, K; Hiraoka, M; Ikushima, H; Kamikonya, N; Kato, D; Nemoto-Murofushi, K; Noda, M; Oya, M; Oya, N; Sakai, Y; Sato, T; Shimada, M; Takeuchi, M; Tomita, N; Watanabe, M; Watanabe, T, 2016) |
| "The purpose of this phase I study of the dose escalation of oxaliplatin in combination with oral S-1 and pelvic radiation preoperatively for poor-risk lower rectal cancer was to determine the dose-limiting toxicity (DLT) and recommended dose of oxaliplatin." | 2.80 | A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis. ( Fujita, S; Hamaguchi, T; Ito, Y; Kinugasa, Y; Moriya, Y; Noura, S; Ohue, M; Saito, N; Sakai, D; Shimada, Y, 2015) |
| "Gemcitabine was administered at an escalating dose of 600, 800 and 1,000 mg/m(2) over 30 min on day 1, and oral S-1 at a dose of 40 mg/m(2) twice daily and oral leucovorin at a dose of 25 mg twice daily on days 1-7, every 2 weeks." | 2.79 | A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Saito, K; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Yamamoto, K; Yamamoto, N, 2014) |
| "To evaluate the efficacy and safety of weekly paclitaxel combined with S-1 or fluorouracil in the first line treatment of advanced gastric carcinoma." | 2.77 | [A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma]. ( Ba, Y; Deng, T; Guo, ZQ; Hu, CH; Huang, DZ; Meng, JC; Wan, HP; Wang, ML; Xiong, JP; Xu, N; Yan, Z; Yao, Y; Yu, Z; Yu, ZH; Zhang, Y; Zheng, RS; Zhuang, ZX, 2012) |
| "Irinotecan (80 mg/m2) was infused on Days 1, 8, 22, and 29." | 2.76 | A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate. ( Hatate, K; Hayakawa, K; Ihara, A; Koizumi, W; Naito, M; Nakamura, T; Okayasu, I; Onosato, W; Ozawa, H; Sato, T; Watanabe, M; Yamashita, K, 2011) |
| " Major adverse effects were hematological toxicities, gastrointestinal disturbance, neurosensory toxicity." | 2.76 | [Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer]. ( Jin, ZM; Zhu, QC, 2011) |
| "We developed a combination chemotherapy, comprising weekly dosing of iv cisplatin (days 1 and 8) combined with a fixed dose (70 mg/m2/day) of S-1 (days 1-14) for patients with metastatic gastric cancer." | 2.72 | [S-1 combined with weekly dosing of cisplatin for metastatic gastric cancer]. ( Hyodo, I, 2006) |
| " After reducing the dosage of S-1, her diarrhea became milder, and she was able to continue S-1 chemotherapy." | 1.48 | The Capsule Endoscopy Findings in S-1-induced Enteritis with Severe Diarrhea during Adjuvant Chemotherapy for Gastric Cancer (with Video). ( Goto, M; Harada, S; Higuchi, K; Kodama, K; Kojima, Y; Nouda, S; Ota, K; Ozaki, H; Takeuchi, T, 2018) |
| "Gemcitabine plus S-1 is a viable treatment alternative to gemcitabine, which is one of the standard treatments in patients with LAPC." | 1.46 | Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. ( Furuse, J; Hamada, C; Ikari, T; Imai, S; Isayama, H; Ishii, H; Nakai, Y; Okamura, S; Okusaka, T, 2017) |
| "To identify predictive markers for gastric cancer treatment in Chinese patients, we evaluated the association between polymorphisms of the gene encoding cytochrome P450 2A6 (CYP2A6) and outcomes of S-1 plus oxaliplatin (SOX) chemotherapy treatment." | 1.46 | CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients. ( Hu, S; Shu, C; Song, Y; Sun, YK; Yang, L; Yang, Y; Yuan, X; Zhang, W; Zhou, A; Zou, S, 2017) |
| "The chemotherapy regime was 80 mg/m(2) liposome-paclitaxel given on days 1, 8, 15 and 22, combined with S-1 60 mg (body surface area > 1." | 1.40 | Effect of the weekly administration of liposome-Paclitaxel combined with s-1 on advanced gastric cancer. ( Chen, L; Chen, Q; Chen, Z; Shen, L; Shen, X; Tao, J; Wang, H; Wang, J; Zhang, Y; Zhu, M; Zhuang, Z, 2014) |
| "In 62 gastric cancer patients treated with S-1 alone, data relating to the occurrence of gastrointestinal toxicity (diarrhea, vomiting, and nausea) and possible contributing factors were retrospectively collected, and logistic regression analysis was performed." | 1.40 | Reduction in gastrointestinal toxicity by gastric secretion inhibitors during S-1 monotherapy for patients with gastric cancer. ( Chisaki, Y; Hira, D; Morita, SY; Noda, S; Terada, T; Yano, Y, 2014) |
| " In the CDHP and Oxo treatment groups of rats, the only toxic signs were soft or diarrheal stools on the dosing day." | 1.29 | [Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo]. ( Hayashi, T; Hirota, T; Irimura, K; Ohmae, S; Tanaka, G, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.41) | 18.2507 |
| 2000's | 9 (24.32) | 29.6817 |
| 2010's | 25 (67.57) | 24.3611 |
| 2020's | 1 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Kawakami, K | 1 |
| Aoyama, T | 1 |
| Yokokawa, T | 1 |
| Kobayashi, K | 1 |
| Takahari, D | 1 |
| Chin, K | 1 |
| Ide, T | 1 |
| Machida, Y | 1 |
| Yamaguchi, K | 1 |
| Hama, T | 1 |
| Hamada, C | 1 |
| Okusaka, T | 2 |
| Ikari, T | 1 |
| Isayama, H | 2 |
| Furuse, J | 3 |
| Ishii, H | 1 |
| Nakai, Y | 2 |
| Imai, S | 1 |
| Okamura, S | 1 |
| Kudo, M | 2 |
| Moriguchi, M | 1 |
| Numata, K | 1 |
| Hidaka, H | 1 |
| Tanaka, H | 1 |
| Ikeda, M | 1 |
| Kawazoe, S | 1 |
| Ohkawa, S | 1 |
| Sato, Y | 1 |
| Kaneko, S | 1 |
| Takeuchi, M | 3 |
| Fang, X | 1 |
| Date, Y | 1 |
| Li, J | 1 |
| Xu, R | 1 |
| Xu, J | 1 |
| Denda, T | 1 |
| Ikejiri, K | 1 |
| Shen, L | 2 |
| Toh, Y | 1 |
| Shimada, K | 1 |
| Kato, T | 2 |
| Sakai, K | 1 |
| Yamamoto, M | 1 |
| Mishima, H | 2 |
| Wang, J | 2 |
| Baba, H | 2 |
| Yang, L | 1 |
| Zou, S | 1 |
| Shu, C | 1 |
| Song, Y | 1 |
| Sun, YK | 1 |
| Zhang, W | 1 |
| Zhou, A | 1 |
| Yuan, X | 1 |
| Yang, Y | 1 |
| Hu, S | 1 |
| Ota, K | 1 |
| Takeuchi, T | 1 |
| Kodama, K | 1 |
| Ozaki, H | 1 |
| Harada, S | 1 |
| Kojima, Y | 1 |
| Nouda, S | 1 |
| Goto, M | 2 |
| Higuchi, K | 1 |
| Winther, SB | 2 |
| Bjerregaard, JK | 1 |
| Schonnemann, KR | 1 |
| Ejlsmark, MW | 1 |
| Krogh, M | 2 |
| Jensen, HA | 2 |
| Pfeiffer, P | 2 |
| Matsuda, C | 1 |
| Honda, M | 1 |
| Tanaka, C | 1 |
| Kondo, K | 1 |
| Takahashi, T | 1 |
| Kosugi, C | 1 |
| Tokunaga, Y | 1 |
| Takemoto, H | 1 |
| Kim, HM | 1 |
| Sakamoto, J | 1 |
| Oba, K | 1 |
| Toyomasu, Y | 1 |
| Mochiki, E | 1 |
| Yanai, M | 1 |
| Suzuki, M | 2 |
| Yanoma, T | 1 |
| Kimura, A | 1 |
| Kogure, N | 1 |
| Ogata, K | 1 |
| Kuwano, H | 1 |
| Chen, L | 1 |
| Chen, Q | 1 |
| Zhuang, Z | 1 |
| Zhang, Y | 2 |
| Tao, J | 1 |
| Shen, X | 1 |
| Chen, Z | 1 |
| Zhu, M | 1 |
| Wang, H | 1 |
| Ohue, M | 1 |
| Hamaguchi, T | 2 |
| Ito, Y | 1 |
| Sakai, D | 1 |
| Noura, S | 1 |
| Kinugasa, Y | 1 |
| Fujita, S | 1 |
| Shimada, Y | 2 |
| Saito, N | 1 |
| Moriya, Y | 1 |
| Nakamura, T | 2 |
| Yamashita, K | 2 |
| Sato, T | 3 |
| Ema, A | 1 |
| Naito, M | 2 |
| Watanabe, M | 3 |
| Chisaki, Y | 1 |
| Noda, S | 1 |
| Hira, D | 1 |
| Morita, SY | 1 |
| Yano, Y | 1 |
| Terada, T | 1 |
| Saito, K | 1 |
| Sasaki, T | 1 |
| Takahara, N | 1 |
| Hamada, T | 1 |
| Mizuno, S | 1 |
| Miyabayashi, K | 1 |
| Yamamoto, K | 1 |
| Mohri, D | 1 |
| Kogure, H | 1 |
| Yamamoto, N | 1 |
| Hirano, K | 1 |
| Ijichi, H | 1 |
| Tateishi, K | 1 |
| Tada, M | 1 |
| Koike, K | 1 |
| Namikawa, T | 1 |
| Munekage, E | 1 |
| Maeda, H | 1 |
| Kitagawa, H | 1 |
| Kobayashi, M | 1 |
| Hanazaki, K | 1 |
| Abdel-Rahman, O | 1 |
| ElHalawani, H | 1 |
| Essam-Eldin, S | 1 |
| Zubcevic, K | 1 |
| Qvortrup, C | 1 |
| Vestermark, LW | 1 |
| Sorbye, H | 1 |
| Satoi, S | 1 |
| Yanagimoto, H | 1 |
| Yamamoto, T | 1 |
| Ohe, C | 1 |
| Miyasaka, C | 1 |
| Uemura, Y | 1 |
| Hirooka, S | 1 |
| Yamaki, S | 1 |
| Ryota, H | 1 |
| Michiura, T | 1 |
| Inoue, K | 1 |
| Matsui, Y | 1 |
| Tanigawa, N | 1 |
| Kon, M | 1 |
| Hayakawa, K | 2 |
| Tomita, N | 1 |
| Noda, M | 1 |
| Kamikonya, N | 1 |
| Watanabe, T | 1 |
| Kato, D | 1 |
| Sakai, Y | 1 |
| Hiraoka, M | 1 |
| Shimada, M | 1 |
| Ikushima, H | 1 |
| Oya, N | 1 |
| Oya, M | 1 |
| Nemoto-Murofushi, K | 1 |
| Arima, S | 1 |
| Shimizu, K | 1 |
| Okamoto, T | 1 |
| Toki, M | 1 |
| Suzuki, Y | 1 |
| Okano, N | 1 |
| Naruge, D | 1 |
| Kawai, K | 1 |
| Kobayashi, T | 1 |
| Kasuga, A | 1 |
| Kitamura, H | 1 |
| Takasu, A | 1 |
| Nagashima, F | 1 |
| Sugiyama, M | 1 |
| Hong, YS | 1 |
| Lee, JL | 2 |
| Park, JH | 1 |
| Kim, JH | 1 |
| Yoon, SN | 1 |
| Lim, SB | 1 |
| Yu, CS | 1 |
| Kim, MJ | 1 |
| Jang, SJ | 1 |
| Lee, JS | 2 |
| Kim, JC | 1 |
| Kim, TW | 2 |
| Ozawa, H | 1 |
| Hatate, K | 1 |
| Onosato, W | 1 |
| Ihara, A | 1 |
| Koizumi, W | 1 |
| Okayasu, I | 1 |
| Chon, HJ | 1 |
| Rha, SY | 1 |
| Park, HS | 1 |
| Shin, SJ | 1 |
| Kim, HS | 1 |
| Roh, JK | 1 |
| Noh, SH | 1 |
| Chung, HC | 1 |
| Jeung, HC | 1 |
| Zhu, QC | 1 |
| Jin, ZM | 1 |
| Komatsu, Y | 2 |
| Yuki, S | 2 |
| Sogabe, S | 1 |
| Fukushima, H | 1 |
| Nakatsumi, H | 1 |
| Kobayashi, Y | 1 |
| Iwanaga, I | 1 |
| Nakamura, M | 1 |
| Hatanaka, K | 1 |
| Miyagishima, T | 2 |
| Munakata, M | 1 |
| Meguro, T | 1 |
| Tateyama, M | 1 |
| Sakata, Y | 1 |
| Huang, DZ | 1 |
| Xiong, JP | 1 |
| Xu, N | 1 |
| Yan, Z | 1 |
| Zhuang, ZX | 1 |
| Yu, Z | 1 |
| Wan, HP | 1 |
| Deng, T | 1 |
| Zheng, RS | 1 |
| Guo, ZQ | 1 |
| Hu, CH | 1 |
| Wang, ML | 1 |
| Yu, ZH | 1 |
| Yao, Y | 1 |
| Meng, JC | 1 |
| Ba, Y | 1 |
| Saeki, T | 1 |
| Takashima, S | 1 |
| Sano, M | 1 |
| Horikoshi, N | 1 |
| Miura, S | 1 |
| Shimizu, S | 1 |
| Morimoto, K | 1 |
| Kimura, M | 1 |
| Taguchi, T | 2 |
| Suzuki, S | 1 |
| Harada, N | 1 |
| Takeo, Y | 1 |
| Tanaka, S | 1 |
| Hayashi, T | 2 |
| Hanyu, F | 1 |
| Goto, A | 1 |
| Yamada, Y | 1 |
| Yasui, H | 1 |
| Kato, K | 1 |
| Muro, K | 1 |
| Shirao, K | 1 |
| Hyodo, I | 1 |
| Asaka, M | 1 |
| Kang, HJ | 1 |
| Kang, YK | 1 |
| Ryu, MH | 1 |
| Chang, HM | 1 |
| Sohn, HJ | 1 |
| Kim, H | 1 |
| Shien, T | 1 |
| Shimizu, C | 1 |
| Akashi-Tanaka, S | 1 |
| Yonemori, K | 1 |
| Kohno, T | 1 |
| Hojo, T | 1 |
| Ando, M | 1 |
| Katsumata, N | 1 |
| Kinoshita, T | 1 |
| Fujiwara, Y | 1 |
| Uedo, N | 1 |
| Narahara, H | 1 |
| Ishihara, R | 1 |
| Takiuchi, H | 1 |
| Fujitani, K | 1 |
| Hirao, M | 1 |
| Tsujinaka, T | 1 |
| Imano, M | 1 |
| Furukawa, H | 1 |
| Tsukuma, H | 1 |
| Tanaka, G | 1 |
| Irimura, K | 1 |
| Hirota, T | 1 |
| Ohmae, S | 1 |
| Shirasaka, T | 1 |
| Shimamoto, Y | 1 |
| Fukushima, M | 1 |
| Yoshisue, K | 1 |
| Hironaga, K | 1 |
| Yamaguchi, S | 1 |
| Yamamoto, A | 1 |
| Nagayama, S | 1 |
| Kawaguchi, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[NCT02163291] | Phase 2 | 30 participants (Anticipated) | Interventional | 2013-12-31 | Not yet recruiting | ||
| Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity in Patients With Solid Tumors: A Retrospective, International and Non-interventional Study[NCT04260269] | 200 participants (Anticipated) | Observational | 2018-06-01 | Enrolling by invitation | |||
| Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer[NCT00569790] | Phase 2 | 53 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for oxonic acid and Diarrhea
| Article | Year |
|---|---|
S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Combinations; Fluorouracil; Humans; I | 2016 |
[Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Topics: Animals; Anorexia; Antimetabolites, Antineoplastic; Diarrhea; Dogs; Drug Combinations; Female; Fluor | 1998 |
23 trials available for oxonic acid and Diarrhea
| Article | Year |
|---|---|
S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Diarrhea; Double-Blind Method; Dru | 2017 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; China; Col | 2017 |
A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Diarrhea; D | 2018 |
A prospective pilot study of an elemental nutritional supplement for prevention of oral mucositis during S-1 adjuvant chemotherapy for gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Case-Control Studie | 2019 |
A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis.
Topics: Adenocarcinoma; Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; A | 2015 |
Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Analysis of Variance; Antineoplastic Combined Chemo | 2014 |
A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Dose-Respon | 2014 |
Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
Topics: Acetamides; Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic | 2014 |
Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2016 |
A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Diarrh | 2016 |
A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Co | 2017 |
Phase I study of preoperative chemoradiation with s-1 and oxaliplatin in patients with locally advanced resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2011 |
A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Disease-Free Su | 2011 |
[Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Colo | 2011 |
Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2012 |
[A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; | 2012 |
[A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Breast Neoplasms; Diarrhea; Drug Administrat | 2004 |
Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agent | 2006 |
[S-1 combined with weekly dosing of cisplatin for metastatic gastric cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplat | 2006 |
[Irinotecan plus oral S-1 in patients with advanced gastric cancer-biweekly IRIS regimen].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cap | 2006 |
Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; | 2008 |
Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002).
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplas | 2007 |
12 other studies available for oxonic acid and Diarrhea
| Article | Year |
|---|---|
The Combined Use of 5 or More Drugs Is a Factor Related to Lower Adherence to S-1 in S-1 and Oxaliplatin Treatment for Advanced Gastric Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2021 |
Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.
Topics: Aftercare; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; | 2017 |
CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients.
Topics: Adult; Aged; Asian People; China; Cytochrome P-450 CYP2A6; Diarrhea; Drug Combinations; Drug Therapy | 2017 |
The Capsule Endoscopy Findings in S-1-induced Enteritis with Severe Diarrhea during Adjuvant Chemotherapy for Gastric Cancer (with Video).
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capsule Endo | 2018 |
S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho | 2018 |
Effect of the weekly administration of liposome-Paclitaxel combined with s-1 on advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Drug A | 2014 |
Reduction in gastrointestinal toxicity by gastric secretion inhibitors during S-1 monotherapy for patients with gastric cancer.
Topics: Aged; Diarrhea; Dose-Response Relationship, Drug; Drug Combinations; Female; Gastric Mucosa; Histami | 2014 |
Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.
Topics: Adult; Aged; Ascites; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuv | 2017 |
[A case of recurrent gallbladder cancer responding to combination chemotherapy of TS-1 and CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Diarrhea | 2004 |
Clinical efficacy of S-1 in pretreated metastatic breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms | 2008 |
[Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo].
Topics: Administration, Oral; Alopecia; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 1996 |
Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Colon; Diarrhea; Digestive System; Drug Combi | 2000 |